Biologics will grow gastrointestinal drugs market to $48.4 billion by 2022, says report

6 October 2016
2019_biotech_test_vial_discovery_big

The value of the global gastrointestinal drug market will reach $48.4 billion within the next six years, says a report from GBI Research.

In the business intelligence provider’s report, a compound annual growth rate (CAGR) of 4.45% is predicted from the 2015 market value of $35.7 billion.

The report notes that the market has been hit by the patent expirations of a number of the leading gastrointestinal products, such as Nexium (esomeprazole) from Anglo-Swedish pharma major AstraZeneca’s (LSE: AZN), and Remicade (infliximab), which is sold by US healthcare giant Johnson & Johnson (NYSE: JNJ).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology